Certara Services Archives

Case Study

运用真实世界证据指导治疗指南制定

Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…

Certara2023 年 4 月 5 日

Case Study

Using Real Word Evidence to Enhance Drug Development

Real-world evidence (RWE) has emerged as an increasingly important tool in the drug development process,1…

Certara2023 年 4 月 5 日

Conference

RAPS Convergence 2025

– – Booth

Certara2023 年 3 月 20 日

Conference

ACCP 年度会议

– – Booth

Certara2022 年 7 月 15 日

Case Study

利用一种罕见病的临床数据支持另一种罕见病的药物审批

Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare genetic disease that causes abnormal blood clot…

Certara2022 年 6 月 1 日

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

Certara2021 年 12 月 15 日

Case Study

Dose Optimization Using Population PK for an Orphan Drug

RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…

Certara2021 年 11 月 17 日

Case Study

通过以数据为导向的科学方法，确定进入市场的路径战略

How Certara supported a gene therapy manufacturer by using a selection of gateway and value…

Certara2021 年 10 月 28 日

White Paper

运用真实世界证据推动新疗法市场准入

Certara2021 年 9 月 29 日

On-Demand Webinar

罕见病管理的“可怕”未来

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…

Certara2021 年 9 月 23 日

Certara 服务

运用真实世界证据指导治疗指南制定

Using Real Word Evidence to Enhance Drug Development

RAPS Convergence 2025

ACCP 年度会议

利用一种罕见病的临床数据支持另一种罕见病的药物审批

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

Dose Optimization Using Population PK for an Orphan Drug

通过以数据为导向的科学方法，确定进入市场的路径战略

运用真实世界证据推动新疗法市场准入

罕见病管理的“可怕”未来

订阅时事通讯

快捷链接

解决方案

联系我们